The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule

Autores
Naidich, Gretel; Santucci, Natalia Estefanía; Pezzotto, Stella Maris; Ceccarelli, Eduardo Augusto; Bottasso, Oscar Adelmo; Perichón, A. Mario
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Anti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies in healthy people at different points of time following the Sputnik immunization procedure. Methods: We attended the vaccination centers in the city of Rosario, which had shorter versus longer intervals between both doses. A total of (1021) adults with no COVID-compatible symptoms (throughout the study period) were grouped according to the gap between both vaccine doses: 21 (Group A, n=528), 30 (Group B, n=147), and 70 days (Group C, n=82), as well as an additional group of individuals with heterologous vaccination (Sputnik/Moderna, separated by a 107- day interval, group D, n=264). Results and conclusions: While there were no between-group differences in baseline levels of specific antibodies, data collected several weeks after administering the second dose showed that group D had the highest amounts of specific antibodies, followed by values recorded in Groups C, B, and A. The same pattern of group differences was seen when measuring anti-S antibodies at 21 or 180 days after the first and second doses, respectively. Delayed betweendose intervals coexisted with higher antibody titers. This happened even more when using a prime-boost heterologous schedule.
Fil: Naidich, Gretel. Centro Unico de Donación, Ablación e Implantación de Organos; Argentina
Fil: Santucci, Natalia Estefanía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Ceccarelli, Eduardo Augusto. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Bottasso, Oscar Adelmo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Perichón, A. Mario. Centro Único de Donación, Ablación E Implante de Órgano; Argentina
Materia
Serology
Vaccinations
Prime-boost
SARS-CoV-2
Antibodies
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/255241
Acceder
id CONICETDig_072fb7d3911cabba2a6d4f3dfe1fcd14
oai_identifier_str oai:ri.conicet.gov.ar:11336/255241
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous scheduleNaidich, GretelSantucci, Natalia EstefaníaPezzotto, Stella MarisCeccarelli, Eduardo AugustoBottasso, Oscar AdelmoPerichón, A. MarioSerologyVaccinationsPrime-boostSARS-CoV-2Antibodieshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: Anti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies in healthy people at different points of time following the Sputnik immunization procedure. Methods: We attended the vaccination centers in the city of Rosario, which had shorter versus longer intervals between both doses. A total of (1021) adults with no COVID-compatible symptoms (throughout the study period) were grouped according to the gap between both vaccine doses: 21 (Group A, n=528), 30 (Group B, n=147), and 70 days (Group C, n=82), as well as an additional group of individuals with heterologous vaccination (Sputnik/Moderna, separated by a 107- day interval, group D, n=264). Results and conclusions: While there were no between-group differences in baseline levels of specific antibodies, data collected several weeks after administering the second dose showed that group D had the highest amounts of specific antibodies, followed by values recorded in Groups C, B, and A. The same pattern of group differences was seen when measuring anti-S antibodies at 21 or 180 days after the first and second doses, respectively. Delayed betweendose intervals coexisted with higher antibody titers. This happened even more when using a prime-boost heterologous schedule.Fil: Naidich, Gretel. Centro Unico de Donación, Ablación e Implantación de Organos; ArgentinaFil: Santucci, Natalia Estefanía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Ceccarelli, Eduardo Augusto. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Bottasso, Oscar Adelmo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Perichón, A. Mario. Centro Único de Donación, Ablación E Implante de Órgano; ArgentinaFrontiers Media2023-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/255241Naidich, Gretel; Santucci, Natalia Estefanía; Pezzotto, Stella Maris; Ceccarelli, Eduardo Augusto; Bottasso, Oscar Adelmo; et al.; The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule; Frontiers Media; Frontiers in Immunology; 14; 4-2023; 1-9CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2023.1141794info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1141794/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:31:35Zoai:ri.conicet.gov.ar:11336/255241instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:31:36.112CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
title The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
spellingShingle The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
Naidich, Gretel
Serology
Vaccinations
Prime-boost
SARS-CoV-2
Antibodies
title_short The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
title_full The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
title_fullStr The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
title_full_unstemmed The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
title_sort The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule
dc.creator.none.fl_str_mv Naidich, Gretel
Santucci, Natalia Estefanía
Pezzotto, Stella Maris
Ceccarelli, Eduardo Augusto
Bottasso, Oscar Adelmo
Perichón, A. Mario
author Naidich, Gretel
author_facet Naidich, Gretel
Santucci, Natalia Estefanía
Pezzotto, Stella Maris
Ceccarelli, Eduardo Augusto
Bottasso, Oscar Adelmo
Perichón, A. Mario
author_role author
author2 Santucci, Natalia Estefanía
Pezzotto, Stella Maris
Ceccarelli, Eduardo Augusto
Bottasso, Oscar Adelmo
Perichón, A. Mario
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Serology
Vaccinations
Prime-boost
SARS-CoV-2
Antibodies
topic Serology
Vaccinations
Prime-boost
SARS-CoV-2
Antibodies
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Anti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies in healthy people at different points of time following the Sputnik immunization procedure. Methods: We attended the vaccination centers in the city of Rosario, which had shorter versus longer intervals between both doses. A total of (1021) adults with no COVID-compatible symptoms (throughout the study period) were grouped according to the gap between both vaccine doses: 21 (Group A, n=528), 30 (Group B, n=147), and 70 days (Group C, n=82), as well as an additional group of individuals with heterologous vaccination (Sputnik/Moderna, separated by a 107- day interval, group D, n=264). Results and conclusions: While there were no between-group differences in baseline levels of specific antibodies, data collected several weeks after administering the second dose showed that group D had the highest amounts of specific antibodies, followed by values recorded in Groups C, B, and A. The same pattern of group differences was seen when measuring anti-S antibodies at 21 or 180 days after the first and second doses, respectively. Delayed betweendose intervals coexisted with higher antibody titers. This happened even more when using a prime-boost heterologous schedule.
Fil: Naidich, Gretel. Centro Unico de Donación, Ablación e Implantación de Organos; Argentina
Fil: Santucci, Natalia Estefanía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Ceccarelli, Eduardo Augusto. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Bottasso, Oscar Adelmo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Perichón, A. Mario. Centro Único de Donación, Ablación E Implante de Órgano; Argentina
description Introduction: Anti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies in healthy people at different points of time following the Sputnik immunization procedure. Methods: We attended the vaccination centers in the city of Rosario, which had shorter versus longer intervals between both doses. A total of (1021) adults with no COVID-compatible symptoms (throughout the study period) were grouped according to the gap between both vaccine doses: 21 (Group A, n=528), 30 (Group B, n=147), and 70 days (Group C, n=82), as well as an additional group of individuals with heterologous vaccination (Sputnik/Moderna, separated by a 107- day interval, group D, n=264). Results and conclusions: While there were no between-group differences in baseline levels of specific antibodies, data collected several weeks after administering the second dose showed that group D had the highest amounts of specific antibodies, followed by values recorded in Groups C, B, and A. The same pattern of group differences was seen when measuring anti-S antibodies at 21 or 180 days after the first and second doses, respectively. Delayed betweendose intervals coexisted with higher antibody titers. This happened even more when using a prime-boost heterologous schedule.
publishDate 2023
dc.date.none.fl_str_mv 2023-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/255241
Naidich, Gretel; Santucci, Natalia Estefanía; Pezzotto, Stella Maris; Ceccarelli, Eduardo Augusto; Bottasso, Oscar Adelmo; et al.; The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule; Frontiers Media; Frontiers in Immunology; 14; 4-2023; 1-9
CONICET Digital
CONICET
url http://hdl.handle.net/11336/255241
identifier_str_mv Naidich, Gretel; Santucci, Natalia Estefanía; Pezzotto, Stella Maris; Ceccarelli, Eduardo Augusto; Bottasso, Oscar Adelmo; et al.; The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals: The positive influence of extended between-dose intervals and heterologous schedule; Frontiers Media; Frontiers in Immunology; 14; 4-2023; 1-9
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2023.1141794
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1141794/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082800885694464
score 13.22299

Publicaciones similares